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Abstract: 
Non-melanoma skin cancers (NMSC) are the most common forms of cancer in the world 
accounting for nearly half of all cancer diagnoses. Rates of NMSC are on the rise with an 
over 300% increase in diagnosis of these cancers in the last 20 years. While 
environmental risk factors for skin cancer such as ultraviolet light (UV) exposure are well 
understood, little is known about inherited genetic risk factors for these cancers. Mouse 
linkage studies have identified several loci housing skin cancer susceptibility genes 
(susceptibility to skin cancer or Skts).  Human tumors show evidence of preferential allelic 
imbalance for polymorphisms in Hdac9, a gene mapping to one of the linkage regions, 
Skts5.  An intron in the Hdac9 gene between exons 8 and 9 was shown by others to 
contain an enhancer for Twist1 which affects early limb development and phenotypes in 
the skin. Twist1 is a known regulator of skin differentiation and has a documented role in 
cancer including metastasis and cell growth. The hypothesis of this study is that this 
enhancer locus plays a role in the differential risk for NMSC between the cancer 
susceptible NIH/Ola and cancer resistant Spretus/EiJ mice.  To test this hypothesis, we 
first looked for sequence differences between the strains. Sequence analyses led to the 
identification of several polymorphisms in this intron which are predicted by multiple in 
silico methods to disrupt known transcription factor binding. To investigate the in vitro 
effects of these variants, intron fragments from both NIH/Ola and Spret/EiJ murine DNA 
were cloned into an enhancer pGL3 reporter vector and transfected into both normal 
keratinocyte C5N and squamous cell carcinoma A5 cells. Luciferase assay and real-time 
PCR data suggests these variants are responsible for changes in gene expression, 
specifically in the Twist1 gene.  Chromatin immunoprecipitation studies found that two 
transcription factors, Gata3 and Oct1, preferentially bind to NIH or Spretus DNA 
respectively at the enhancer locus, suggesting a possible mechanism for enhancer 
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activity. In summary, variants at the Hdac9 intron 8 enhancer appear to affect Twist1 
expression and may explain the skin cancer susceptibility locus Skts5.  
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                                                    CHAPTER 1: INTRODUCTION 
 
Non-Melanoma Skin Cancer (NMSC):  
Non-melanoma skin cancer is a broad category of metastatic disease that accounts for 
nearly 3.5 million cancer diagnosis in the United States each year (Skin Cancer 
Foundation, SCF).The two most common forms of NMSC include basal cell carcinoma 
(BCC), a cancer originating in the basal cells of the epidermis, and squamous cell 
carcinoma (SCC), which initiates in the keratinocytes of the epidermis. These two types 
of NMSC account for roughly 96% of all NMSC diagnoses each year, with 80% of cases 
classified as BCC. Other rare non-melanoma skin cancers include Kaposi’s sarcoma, 
normally seen only in immunocompromised patients, and Merkel cell carcinoma, a 
neuroendocrine related cancer usually developing in the hair follicles (UCSF 
Dermatology). These cancers do not include melanomas, which alternatively result from 
malignancies originating in pigment producing melanocytes. 
While instances of mortality resulting from NMSC are low, rates of recurrence are high 
and NMSC patients are at increased risk for developing other cancers. The cost of 
NMSC treatments are a significant financial burden, totaling over 1.4 billion dollars in 
2004 (SCF). Alarmingly, there has been a 300% increase in the incidence of skin 
cancers since 1994 (SCF). This increase can be partially attributed to a rise in 
environmental risk factors, most notably increased ultraviolet light (UV) exposure 
resulting from a depleted ozone layer and a rise in tanning bed usage. Other NMSC risk 
factors include: light skin and eye color, family and personal history, smoking, radiation 
or chemical carcinogen exposure and immunosuppressive medical conditions 
(Cancer.gov).  While it is understood there is a genetic component of risk, the exact 
genetic risk factors and mechanism of SCC development is poorly understood to date.  
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Skin Tumor Susceptibility Locus 5 (Skts5):                                                                          
Linkage analysis using F1 backcrosses between skin cancer resistant Mus spretus and 
susceptible Mus musculus mice has led to the identification of a susceptibility locus for 
skin cancer on mouse chromosome 12, called Skts5 (Mahler et al. 2008). In humans, the 
orthologous locus mapping to 7p21 and 7q31 has also been identified as a susceptibility 
locus through allelic imbalance studies (Fleming et al. 2014). The human studies 
revealed that roughly 20% of cutaneous SCC tumors exhibit copy neutral loss of 
heterozygocity and copy number increases are present in 10% of tumors. Additionally, 
microsatellite markers within Skts5 show preferential allelic imbalance in SCC tumors. In 
humans, nine single nucleotide polymorphisms (SNPs) mapping to Hdac9 within Skts5 
demonstrated significant preferential allelic imbalance in SCC tumors, suggesting that 
Hdac9 or variants mapping near Hdac9 may be important in human SCC.  
 
Genetic Enhancers:                                                                                                          
Enhancers are short DNA sequences that act as cis or trans-regulatory genetic 
elements, increasing the expression of a target gene. Enhancers exhibit their effects 
through binding specific transcription factors that favorably interact with the promoter 
and transcription initiation site of the target gene, increasing levels of transcription and 
thus gene expression. Enhancers can be found either upstream or downstream of the 
target gene, as long as their spatial organization in the nucleus allows interaction with 
the target gene. They can be located hundreds or thousands of base pairs away from 
this gene of interest, and can be found in either coding regions of the genome or in non-
coding elements such as introns.  A unique feature of enhancers is their ability to exhibit 
regulatory effects independent of their orientation, functional in both forward and reverse 
sequential order (Tuan et al. 1997). Enhancers have been implicated in many pathologic 
conditions including several cancers. Pancreatic cancer and skin cancer risk specifically 
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have been associated with enhancers in non-coding regions of the genome (Hurst et al. 
2002 and Takahara et al. 2010).  
 
Histone Deacytelase 9 (Hdac9) and Twist1: 
Histone deacetylase 9 (Hdac9) is a gene located on mouse chromosome 12 and human 
chromosome 7 that codes for a catalyzing enzyme that removes acetyl groups of 
histones. Hdac9 is a member of the histone deacetylase family of genes that all code for 
enzymes involved in acetyl group removal and transcription regulation (Kuilenburg et al. 
2003). In skin cancer, polymorphisms in Hdac9 have been associated with genetic risk 
through linkage analysis and allelic imbalance studies (Fleming et al. 2014). A nearby 
gene to Hdac9 in both mice and humans is Twist1, an oncogene known to play several 
roles in tumurogenesis including but not limited to metastasis, apoptosis inhibition and 
epithelial mesenchymal transition or EMT (Geng et al. 2009). Overexpression of Twist1 
has been implicated in several forms of cancer including various carcinomas, and the 
gene is a potential target for cancer therapeutics (Fu et al. 2013). Both Twist1 and 
Hdac9 map to the peak region of linkage for Skts5 (Mahler et al. 2008). 
A known cis-regulatory association between Hdac9 and Twist1 has been shown in mice 
in the form of an enhancer that has been demonstrated to affect limb development and 
skin phenotypes in vivo (Ahituv et al. 2012). In this study, human Hdac9 DNA mapping 
to the orthologous 8-9 intron of murine Hdac9 was cloned into an Hsp68-LacZ enhancer 
reporting vector. Enhancer assays revealed the Hdac9 locus was acting as an enhancer 
for Twist1, increasing expression levels in the skin and limbs. Mice lacking this enhancer 
demonstrated phenotypes of polydactyly and abnormal skin development with partial 
penetrance. Similar results were observed in zebrafish. The genetic locus of interest 
showing the proximity of these genes in mice and humans is shown in Figure 1.  
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                                                          FIGURE 1 
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Figure 1: Map of Skts5 region of interest in humans and mice showing the spatial proximity of Hdac9 
and Twist1. Human region displayed is estimated to be 2.2 Mb in length. Mouse region is estimated to 
be 1.8 Mb in length. 
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Hypothesis and Specific Aims: 
The central hypothesis of my research is that variants in the proposed enhancer region 
of Hdac9 between skin cancer resistant Spretus and susceptible NIH/Ola murine DNA 
are driving differential gene expression of enhancer target genes, contributing to the 
differential risk for skin cancer seen between these two mice strains. The specific aims 
of this project are outlined below: 
1. To determine if variants exist between NIH/Ola and Spretus murine DNA at the 
proposed enhancer locus in Hdac9 between exons 8 and 9.  
2. To identify and characterize any enhancer sites in the murine Hdac9 sequence 
between exons 8 and 9. This will be accomplished by cloning Hdac9 intron 
fragments into an enhancer reporting vector, transfecting these constructs into 
keratinocyte and squamous cell carcinoma cell lines, and using these cells for 
Luciferase assays. 
3. To determine which gene(s) are targets of the enhancer(s) and demonstrate this 
regulation through quantitative PCR.  
4. To identify specific transcription factor/DNA binding interactions potentially   
       associated with enhancer activity. First, in silico prediction tools will be utilized to   
       identify potential factors. Then chromatin immunoprecipitation (ChIP) studies   
       will be performed to demonstrate these interactions in vitro . 
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                             CHAPTER 2: MATERIALS AND METHODS 
2.1 DNA Sample Source: 
Tail snips for NIH/Ola mice were provided by Dr. Allan Balmain and tissues for 
SPRET/Outbred mice were provided by Hiroki Nagase from mice used for other studies as 
approved by the University of California, San Francisco Institutional Animal Care and Use 
Committee.  DNA was isolated from tails using standard methods (Laird et al. 1991). 
2.2 Sequencing: 
Intronic and exonic sequences of the Hdac9 gene corresponding to the published 
enhancer region were identified using the Ensembl database.  We designed PCR primers 
using Integrated DNA Technology’s SciTools PrimerQuest web-based program. PCR 
products were treated with Exo/SAP-IT to remove single stranded DNA (USB).  Automated 
sequencing of PCR products was conducted on an ABI 3700 by standard methods at the 
Ohio State Nucleic Acid Shared Resource. Sequences were analyzed using DNAstar 3.0 
software and polymorphisms were visually inspected when a nucleotide substitution was 
indicated. Sequencing primers are available for reference in Table 1.1 
2.3 Cloning 
Cloning was accomplished using TA Cloning (Graham et al. 1990). Hdac9 intron 8 DNA 
was amplified using Polymerase Chain Reaction. Due to the large intron size of over 5000 
base pairs, nine primer sets were utilized to break up the intron into smaller fragments of 
500-800 base pairs. A model displaying these fragments, categorized as Inserts 1-9, can 
be seen in Figure 2 below. The vector chosen for the cloning process was the pGL3 
enhancer vector complete with an SV40 minimal promoter, a luciferin reporter gene and a 
blunt restriction enzyme digest site for enhancer insertion (Promega). Sma1 blunt-end 
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restriction enzyme digestion was utilized to linearize the vector and 2mM dTTP’s were 
added in a ligation to create a thymine base pair overhang. Hdac9 Insert PCR product was 
ligated to this modified vector to re-circularize the cloning product. Cloning products were 
transformed into Stellar Competent Cells according to Protocol PT5055-2 (Clontech). 
Clones were picked and DNA was isolated using a GeneJET Plasmid Miniprep Kit 
(Thermal Scientific) and stored at -20°C. All clones were verified using both restriction 
enzyme digest and sequencing techniques.  
FIGURE 2: Magnified map of the Hdac9 Intron 8 locus. The intron was divided into 500-
800 bp pieces by customer primer PCR into the self-titled “Inserts 1-9” spanning the length 
of the intron. Primers for these inserts can be found in Table 1.1 
 
2.4 Cell Lines 
Two cell lines were used for the experiments in this project. A normal murine keratinocyte 
cell line, C5N, and a murine cutaneous spindle cell line, A5, were both obtained from Allan 
Balmain (Zoumpourlis et al. 2003). All cells were grown in Dulbecco’s medium (DMEM) 
supplemented with 10% fetal bovine serum (Invitrogen) and 1% penicillin/streptomycin 
(Invitrogen).  
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2.5 Transfection 
Transient transfections were performed using Lipofectamine reagent according to the 
manufacturer’s protocol. Cells were plated in triplicate and were transfected at 60-80% 
confluency. Mock transfection and pGL3-control empty vector only transfections were 
carried out as controls. Cells were also co-transfected with a pRL-TK Renilla reporter gene 
vector as a normalizing control.  
2.6 Luciferase Assays 
Cells were allowed to incubate at 37°C in supplemented DMEM (10% FBS, 1% P/S) for 24 
hours post-transfection. At this time-point cells were harvested and protein lysate was 
prepared using M-PER (Pierce Biotechnology, Rockford, IL). 30 μg of each sample was 
used for luciferase assay analysis, which was performed as described in Skeeles et al. 
2013. Illumination measurements were made using the Veritas Microplate Illuminometer. 
Student t-tests were used to calculate p-values. 
2.7 Quantitative Real-Time PCR 
At 24 and 48 hours post-transfection, cells were harvested and RNA was isolated using a 
modified Trizol protocol (Life Sciences Technologies). One microgram of RNA from each 
sample was reversed transcribed using iScript cDNA synthesis kit (Bio-Rad, Hercules, 
CA).  To assess mRNA expression of Hdac9 and Twist1, Taqman probes were purchased 
from Applied Biosystems (Life Sciences Technologies).  Each sample was measured in 
triplicate. To measure expression of Hdac9 and Twist 1, mRNA expression was measured 
at 24 and 48 hours post-transfection of the pGL3-enhancer construct in A5 cells.  Taqman 
probes were from Applied Biosystems/Life Technologies and are as follows Hdac9 
(Mm00458454), Twist1 (Mm00442036) and Hprt (Mm00446968).  Control gene Hprt was 
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used to calculate the relative expression of each test gene. Each sample was assessed in 
triplicate. Student t-tests were used to calculate the p-values for comparisons.  
2.8 In Silico Predictions for Transcription Factor Binding Sites 
Software tools were utilized to identify potential transcription factor binding differences at 
the Hdac9 intron 8 Locus between NIH/Ola and Spretus murine DNA. TFSearch was the 
primary tool utilized, with a threshold score of 85.0 used as a cutoff for significance. Other 
databases utilized include PROMO (Transfac), TFSitescan (no longer available) and DBD. 
Factors given the most importance were those with high threshold scores and agreement 
between multiple databases.  
2.9 Chromatin Immunoprecipitation (ChIP) 
Chromatin Immunoprecipitation studies were completed using an altered Millipore ChIP 
protocol. Hdac9 transfected cells were grown to a count of one million cells in a 10cm dish 
24 hours post-transfection. Histones were cross-linked with a 1% formaldehyde solution in 
supplemented DMEM (10% FBS, 1% P/S) for 10 min at 37°C. Harvested cells were 
suspended in 500 μL of SDS lysis buffer and sonicated using the Fisher Scientific Sonic 
Dismembrator Model 500 at the following conditions: 12 total cycles of 30 second 
sonication, 60 second rest at 40% amplitude and 4°C.  These conditions consistently 
produced PCR products between 200-400 base pairs. Immunoprecipitation antibodies 
were ordered for transcription factors Oct1 (Bethyl Laboraties No. A301-716A) and Gata3 
(Santa Cruz Biotech HG3-31: sc-268). A no antibody negative control, as well as a non-
specific binding negative control antibody for GFP (Santa Cruz Biotech B-2: sc9996) were 
utilized. Results were displayed both qualitatively and quantitatively, with all quantification 
being performed using the Alpha Imager software. Significance for all data was 
determined using a student t-test.  
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 2.10 Primers  
 TABLE 1.1: Primers for Sequencing and TA Cloning 
 
 Note: Primers for NIH and Spretus were made identical when possible. All primers listed    
 in a 5’        3’ direction 
 
 
 
  
   Amplified DNA 
 
               Forward 
 
                   Reverse 
NIH Insert 1 GCACTTGCAAACAACTGAAGGGTG GGGCAGATCTCCAGCTCATTATTC 
Spretus Insert 1 GCACTTGCAAACAACTGAAGGGTG AAATCACCATTGGCTTTCCCTCGC 
NIH Insert 2 CAGATGACACTTGGCAGCTTGTCT ACTTTGGGCTTCTATTGCTAGCCT 
Spretus Insert 2 CAGATGACACTTGGCAGCTTGTCT ACTTTGGGCTTCTATTGCTAGCCT 
NIH Insert 3 AGGCTGTGTTGAAGGCTAGAGA ATGGGTGTTTCAGCATCTTGTGGC 
Spretus Insert 3 AGGCTGTGTTGAAGGCTAGAGA ATGGGTGTTTCAGCATCTTGTGGC 
NIH Insert 4 ATGGGTGTTTCAGCATCTTGTGGC ACATTCCCTAGCACTGGGCAGAAA 
Spretus Insert 4 ATGGGTGTTTCAGCATCTTGTGGC CTGAGCTTGTTTCTCCATGACAAC 
NIH Insert 5 TATTTCCACTTCCCAGAGCACAGC AGCAAGAGTCAGGGTTGGTTGGAT 
Spretus Insert 5 CTTCCCAGTGCTAGGGAATGTA AGCAAGAGTCAGGGTTGGTTGGAT 
NIH Insert 6 CTAGCATTGCTTCAGGATTGGGATG TTTCCTTTGCATAGCACACACGCC 
Spretus Insert 6 TCCATGAACACTCATCTCAAGCA AAGCCTCATTCCAGTGGATGCTGA 
NIH Insert 7 TTCTTACCTGCCTGAGCAGCATGA GGCTTTCCCACACTTCCACAACTT 
Spretus Insert 7 ATACCCTAAAGGTGACGAGCAAGC GCGCAGGGATTTATGCAATCCAGT 
NIH Insert 8 CCTTGTTACCCTCTTTATTGTTTCCA AACTAGCCTCATTGGCCTCTGGAA 
Spretus Insert 8 AGTGTGGGAAAGCCAGAAACCTGA GAGTGAAATGTACAGGATGCTGGG 
NIH Insert 9 TCTGTGAGCCATAGATCCTCCTGA CCATGGTGAACATCCTACAGGGAA 
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 Table 1.2: Chromatin Immunoprecipitation (ChIP) Primers 
 
 Note: All primers are listed in a 5’       3’ direction. The “Insert 1” portion of Hdac9 intron 8   
 was targeted for ChIP studies for its promise as an enhancer locus from Luciferase Assay  
 and qPCR results. Since multiple transcription factor binding site differences between NIH  
 and Spretus DNA were predicted in this portion of the intron, the insert was divided into  
 smaller “regions” of 200-250 base pairs for more specified analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   Amplified DNA 
 
               Forward 
 
                   Reverse 
Insert 1: Region 1 
 (base pairs 2-242)  
GATTGTAGATCTGGTATGTATGCCT GATCTGCGCCTTCTTCTCATTA 
Insert 1: Region 2 
(base pairs 273-472) 
TGATACTTCCACAGTTAAATAGCAC TCACAGTGACATGTTGACTTGTTT 
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                                               CHAPTER 3: RESULTS 
Identification of Sequence Variants between NIH/Ola and Spretus Murine DNA 
To investigate potential enhancer activity and its relation to skin cancer risk, all genetic 
differences within Hdac9 intron 8 between cancer susceptible NIH/Ola and cancer 
resistant Spretus murine DNA were characterized. To accomplish this, the Hdac9 intron 8 
DNA for both mice strains were amplified and sequenced in small portions (Figure 2). 
Primers for this PCR amplification can be found in Table 1.1. In total, 44 polymorphisms 
were found between the two mice strains.  
                                                           
                                                          TABLE 2   
  
    SNP # 
  Locus of SNP 
  base pair # in   
  Hdac9 Intron 8 
 
NIH Allele Spretus Allele Polymorphism 
1 158 T C TC 
2 334 G C GC 
3 414 C T CT 
4 491 A G AG 
5 534 A G AG 
6 594 G A GA 
7 743 G T GT 
8 744 C X CDELETION 
9 797 A X ADELETION 
10 811 A X ADELETION 
11 1,521 A G AG 
12 1,553 A G AG 
13 1,622 C T CT 
14 1,657 A C AC 
15 1,768 T C TC 
16 1,918 A C AC 
17 2,045 A G AG 
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                                                  TABLE 2  CONTINUED                     
 
 
  
   SNP # 
 Locus of SNP 
  base pair # in   
 Hdac9 Intron 8 
 
NIH Allele Spretus Allele Polymorphism 
18 2,048 G A GA 
19 2,055 G A GA 
20 2,064 G A GA 
21 2,072 A G AG 
22 2,110 T C TC 
23 2,245 T C TC 
24 2,344 G T GT 
25 2,363 G A GA 
26 2,367 X C DELETIONC 
27 2.451 T A TA 
28 2,465 G A GA 
29 2,466 G A GA 
30 2,559 T C TC 
31 2,626 T G TG 
32 2,696 A G AG 
33 2,792 C T CT 
34 2,880 A T AT 
35 3,288 T C TC 
36 3,290 T A TA 
37 3,301 T C TC 
38 3,433 G A GA 
39 3,438 T C TC 
40 3,440 C G CG 
41 3,482 CACACA XXXXXX CACACADELETION 
42 3,495 GT XX GTDELETION 
43 3,499 AT XX ATDELETION 
44 3,502 TATA XXXX TATADELETION 
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Hdac9 Intron Demonstrates Enhancer Activity 
To determine whether or not enhancer activity was present in Hdac9 intron 8, fragments of 
intron DNA were cloned into a pGL3 enhancer reporting vector using TA cloning. The 
fragments of the intron were broken up into 9 DNA segments using the primers found in 
Table 1.1 and a visual of these 9 inserts can be found in Figure 2. Of the 9 total inserts, 3 
have been successfully cloned into the pGL3 vector and confirmed with sequencing. 
These 3 inserts include Insert 1, Insert 2 and Insert 7. The vectors containing each of 
these inserts were transfected into C5N and A5 cell lines and luciferase assays were 
performed on cell harvests 24 hours post-transfection. 
 
Luciferase assay data for Insert 1 suggests enhancer activity is present in both A5 and 
C5N cells transfected with the NIH Insert 1 construct. An estimated 1.6 fold increase in 
Luciferin expression in these cells compared to cells transfected with pGL3 control vector 
is a significant increase in both cell lines (C5N: p<0.01, A5: p<0.01; Figure 3A,B). 
Additionally, enhancer activity seems to be found selectively in the NIH Insert 1 
transfected cells in comparison to the Spretus Insert 1 transfected cells. Differences in 
Luciferin expression were statistically significant in both C5N cells and A5 cells (C5N: 
p<0.05, A5: p<0.01; Figure 3A,B).  
 
Luciferase Assay data for Insert 2 suggests there is also enhancer activity present in cells 
transfected with the NIH Insert 2 construct. Activity was slightly less than Insert 1, with an 
estimated 1.3 fold increase in Luciferin expression in NIH Insert 2 cells in comparison to 
pGL3 control vector transfected cells. Still, these differences were statistically significant 
according to a student t-test (C5N: p<0.05, A5: p<0.05; Figure 3A,B). Similar to Insert 1, 
cells transfected with Insert 2 selectively show enhancer activity in NIH Insert 2 cells in 
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comparison to Spretus Insert 2 transfected cells. These differences also hold statistical 
significance with differences in A5 cells reaching a level of high significance (C5N: p<0.05, 
A5: p<0.01; Figure 3A,B).  
 
Finally, data from Insert 7 Luciferase Assays suggest that enhancer activity was not 
present in this region of the intron. There is no apparent difference in enhancer activity 
(Figure 3A,B).  
 
                                                               Figure 3 
 
 
 
Figure 3A) Luciferase assay data for cells transfected into A5 cells (SCC). Both 
Inserts 1 and 2 show highly significant statistical differences between both control and 
NIH results (**p<0.01). Insert 1 shows highly significant differences between NIH and 
Spretus results (**p values <0.01). Insert 2 shows significant differences (*p<0.05). 
There are no significant changes in expression for Insert 7.  
** 
** 
** 
* 
        Mock                     pGL3 Control                 pGL3 + NIH              pGL3 + Spretus 
A 
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Figure 3B) Luciferase assay data for cells transfected into C5N (normal keratinocyte) 
cells. Insert 1 shows highly significant differences in expression between control and 
NIH results (**p values < 0.01). Insert 2 shows significant differences between control 
and NIH (*p<0.05). Inserts 1 and 2 show significant difference between NIH and 
Spretus (*p<0.05). Insert 7 does not show any significant changes in expression.  
** 
* 
* 
* 
B 
        Mock                      pGL3 Control                 pGL3 + NIH              pGL3 + Spretus 
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Hdac9 Intronic Enhancer Upregulates Twist1 Expression 
To identify target genes of the enhancer activity present in Hdac9 intron 8, Real time 
quantitative PCR studies (qPCR) were performed to look for changes in gene expression 
in the presence of intron DNA constructs. Logical starting genes were Hdac9 and Twist1, 
due to the increased likelihood that the enhancer acts autonomously or on a nearby gene. 
As Twist1 has already been implicated to be a target of Hdac9 enhancer activity, it was 
important to include (Ahituv et al. 2012).  No differences in expression for Hdac9 were 
present between either contruct or controls. It should be noted that expression levels 
relative to control gene Hprt were quite low, possibly indicative of errors in the 
experimentation process.  
 
Results for Twist1 expression assays indicate that the Hdac9 Insert 1 enhancer construct 
is upregulating expression of Twist1. An estimated 2.2 fold increase in expression 
between pGL3 control vector transfected A5 cells and NIH Insert 1 transfected cells is 
apparent with highly significant differences (p<0.01). There also seems to be an estimated 
2 fold increase in expression between NIH Insert 1 transfected cells and Spretus Insert 1 
transfected cells, with significant differences in expression  (p<0.05).  Results for qPCR 
studies analyzing Twist1 expression relative to Hprt control gene can be found in Figure 4.   
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Figure 4) qPCR results for Twist1 expression relative to Hprt control gene. A5 cells 
transfected with NIH Insert 1 contructs show highly significant differences in Twist1 
expression in comparison to pGL3 control (**p<0.01). Significant differences in Twist1 
expression present between NIH Insert 1 and Spretus Insert 1 transfected A5 cells 
(*p<0.05). Results indicate Twist1 is a target for Hdac9 enhancer activity and may play 
a role in the differential risk for skin cancer noted between NIH/Ola and Spretus mice.  
** 
* 
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In Silico Transcription Factor Binding Site Predictions 
To determine which DNA/protein interactions are contributing to enhancer activity, we first 
utilized bioinformatics tools to predict binding differences between NIH and Spretus DNA. 
The primary software tool utilized for this analysis was TFSearch, powered by the 
Transfac 3.0 database. Other secondary analysis tools utilized include PROMO, DBD, and 
TFSiteScan (no longer in existence). Of the hundreds of factors initially available as 
candidates, results were narrowed down through cross-checking across multiple 
databases. From this list, factors were further narrowed according to their significance in 
the field of cancer research according to published literature. The top seven transcription 
factors remaining can be found in Table 3 below along with the polymorphisms that lead 
each factor to differentially bind. A cutoff score of 85.0 (as determined by TFSearch 
database) was utilized for significance.  
 
 
                                                                Table 3 
  
 
 
 
Transcription Factor 
 
 DNA Binding Site 
 
Polymorphism 
 
Binding Strain 
 
Significance Score 
Oct1 ATATACACT G/C Spretus 89.7 
Gata3 AATCACG C/T NIH 85.9 
CdxA ATATAG G/C NIH 85.0 
Lyf-1 TGGGAT A/G Spretus 85.7 
Gfi-1 ATAGTTGTGAT A/G Spretus 85.9 
Nkx-2 TCAAGTG C/A Spretus 89.9 
AP-1 GTGATTAA A/G NIH 86.4 
Table 3) In Silico predictions of transcription factors that will differentially bind NIH and 
Spretus DNA at the enhancer locus in Hdac9. Cutoff score of 85.0 used for significance. 
These factors will be ideal candidates for ChIP studies to confirm predictions in vitro. 
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Gata3 and Oct1 Transcription Factors Bind Hdac9 Enhancer Differentially in vitro 
To test whether or not in silico transcription factor binding predictions actually occurred in 
in vitro cell models, chromatin immunoprecipitation (ChIP) studies were performed utilizing 
antibodies against the Gata3 and Oct1 transcription factors. These factors were selected 
from Table 3 for their binding site loci occurring within Insert 1 of Hdac9 insert 8, which 
displayed the most enhancer activity in luciferase assay results. ChIP results for the Gata3 
factor indicate that Gata3 selectively binds to the NIH/Ola strain of murine DNA in 
comparison to Spretus DNA and controls. An observable increase in DNA binding the 
Gata3 transcription factor in Region 2 of Insert 1 can be seen in C5N cells (Figure 5A). An 
observable difference in Gata3 binding between the two mice strains was not noticeable in 
Region 1 of Insert 1 (Figure 5A). 
 
ChIP results for the Oct1 factor indicate that Oct1 selectively binds the Spretus strain of 
murine DNA in comparison to NIH/Ola controls. An observable increase in DNA binding 
the Oct1 transcription factor can be seen in Regions 1 and 2 of Insert 1 in C5N cells 
(Figure 5B). ChIP experiments in C5N cells confirm the predicted transcription factor 
binding results from the bioinformatics tools utilized in this project.     
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                                                                   Figure 5 
 
 
 
 
 
 
 
 
 
 
 
 
                                               
Figure 5: ChIP results for Gata3 and Oct1 transcription factors. Gata3 shows 
significant preferential binding to NIH DNA in Insert 1 Region 2. Oct1 shows significant 
preferential binding to Spretus DNA in Insert 1 Regions 1 and 2 
A 
B 
28 
 
                                        CHAPTER 4: DISCUSSION 
We hypothesized that variants in a proposed enhancer locus at Hdac9 intron 8 between 
cancer susceptible NIH/Ola and cancer resistant Spretus murine DNA are playing a role 
in the differential risk for NMSC seen between these two mice strains. To support this 
hypothesis, experiments were conducted to both identify genetic differences at this locus 
and determine whether these differences had any effect on enhancer activity in normal 
keratinocyte and SCC cells. Furthermore, we hoped to elucidate the mechanism for this 
difference in risk by identifying genetic targets of this enhancer and determining what 
protein/DNA interactions in the cell nucleus were involved in any differential enhancer 
activity between the mice strains. In summary, this study had four major aims: 
 
1. To determine if variants exist between NIH/Ola and Spretus murine DNA at the 
proposed enhancer locus in Hdac9 between exons 8 and 9.  
2. To identify and characterize any enhancer sites in the murine Hdac9 sequence 
between exons 8 and 9. This will be accomplished by cloning Hdac9 intron 
fragments into an enhancer reporting vector, transfecting these constructs into 
keratinocyte and squamous cell carcinoma cell lines, and using these cells for 
Luciferase assays. 
3. To determine which gene(s) are targets of the enhancer(s) and demonstrate this 
regulation through quantitative PCR.  
4. To identify specific transcription factor/DNA binding interactions potentially   
       associated with enhancer activity. First, in silico prediction tools will be utilized to   
       identify potential factors. Then chromatin immunoprecipitation (ChIP) studies   
       will be performed to demonstrate these interactions in vitro . 
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Hdac9 Variants Alter Enhancer Activity between NIH and Spretus DNA 
Based on our results, clear genetic variation at Hdac9 intron 8 exists between cancer 
susceptible NIH and cancer resistant Spretus murine DNA. In total, 44 genetic variants 
were discovered over the span of a genetic sequence roughly 5,000 base pairs in length. 
Due to the nature of this sequence being intronic, none of these variants are found in 
known protein-coding regions of the genome. However, the potential still exists for these 
variants to be involved in cis-regulatory elements such as enhancers. 
Previous studies have identified enhancer activity in Hdac9. This finding was 
demonstrated using enhancer assays, in which vectors containing human Hdac9 
sequence were cloned into mouse and zebrafish models. In the presence of the human 
Hdac9 sequence mapping to the orthologous mouse Hdac9 intron 8, both mice and 
zebrafish clearly showed enhancer activity using LacZ and GFP reporter genes, 
respectively. Further experimentation showed this Hdac9 enhancer upregulated 
neighboring gene Twist1, with significant potential phenotype implications. In the 
presence of the Hdac9 enhancer, both mice and zebrafish exhibited limb malformations 
(such as polydactyly) and defects in both anterior and posterior limbs (Ahituv et al. 
2012). Interestingly, although Hdac9 is not expressed highly in the limbs, Hdac9 
knockout mice show a similar phenotype to Twist1 knockout mice, indicating enhancer 
activity in Hdac9 may be is essential for sufficient Twist1 expression during 
development.   
In addition to its functionality as an enhancer for Twist1, Hdac9 has also been implicated 
to be part of a skin tumor susceptibility locus known as Skts5. Linkage analysis studies 
in mice have identified variations resulting in amino acid differences in Hdac9 associated 
with differential risk for skin cancer between NIH/Ola and Spretus mice. However, no 
mechanism has been suggested for how these variants affect NMSC genetic risk. 
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A correlation between Hdac9 enhancer activity and the gene’s role in differential risk for 
NMSC has never been investigated. This study attempts to find a link between enhancer 
activity in Hdac9 and the role Hdac9 plays in the differential risk for skin cancer with the 
hope of elucidating a mechanism of Skts5’s relation to NMSC risk. To establish this 
correlation, first enhancer activity had to be demonstrated in our genetic locus within 
mouse Hdac9, as was found in the orthologous genetic locus of human Hdac9. 
Luciferase assay data clearly suggests enhancer activity is indeed present in the Insert 1 
and Insert 2 regions of Hdac9 intron 8. This data establishes that the mice strains 
utilized in this study display similar enhancer activity to previous studies utilizing human 
Hdac9 in mice and zebrafish (Ahituv et al. 2012). While this connection is important, the 
more notable takeaway from these assays is that enhancer activity significantly varies 
between NIH/Ola and Spretus transfected cells. While not proof of causation, this finding 
is instrumental to the hypothesis that enhancer activity is associated with NMSC 
differential risk.  
To further investigate the potential existence of a link between Hdac9 enhancer activity 
and this gene’s role in NMSC risk, Insert 1, the most promising locus for enhancer 
activity studied, was analyzed further to identify gene targets of the enhancer. While 
other inserts were not ruled out as potential enhancer loci, Insert 1’s proven role in 
enhancer activity made it ideal for further experiments.   
 
Hdac9 Intronic Enhancer Upregulates Twist1 Expression 
Based on qPCR results, Hdac9 enhancer does not autonomously regulate Hdac9 
expression. However, the neighboring gene to Hdac9, Twist1, is clearly upregulated in 
the presence of NIH/Ola Hdac9 Insert 1. Interestingly, this upregulation of Twist1 is not 
found in the presence of Spretus Insert 1 or related controls. The discovery that NIH 
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Hdac9 selectively increases expression of Twist1 has significant implications for this 
study. Twist1 overexpression has been linked to several cancer phenotypes including 
apoptosis inhibition, increased cell proliferation and increased epithelial mesenchymal 
transition (EMT) leading to increased metastasis (Geng et al. 2009). If cancer 
susceptible NIH/Ola mice are overexpressing a known oncogene that cancer resistant 
Spretus mice are not overexpressing, this suggests a possible mechanism for the 
reduced rates of NMSC development in Spretus mice. Additionally, this provides strong 
support for our hypothesis that enhancer activity in Hdac9 is directly correlated to 
Hdac9’s role in differential NMSC risk.  
While this discovery is important, it does not elucidate how genetic variants are affecting 
the expression of Twist1. To understand this relationship, specific protein and DNA 
binding interaction differences between NIH and Spretus would have to be 
demonstrated.   
 
Gata3 and Oct1 Transcription Factors Differentially Bind Hdac9 at Insert 1 
Gata3 and Oct1 were selected from Table 3 as the two top candidate transcription 
factors for ChIP studies. These factors have both been implicated previously in risk for 
several cancers including skin cancer and breast cancer (Nielsen et al. 2008, Sturm et 
al. 1993). Additionally, the binding sites for both of these factors occur in Insert 1 of 
Hdac9 intron 8, the insert showing most enhancer activity in luciferase assays (Figure 3).  
According to the ChIP results presented here, Gata3 transcription factor (TF) selectively 
binds NIH murine DNA at the Insert 1 Region 2 predicted binding site in vitro. The role of 
Gata3 in skin cancer is poorly understood, however it is possible Gata3 binding to NIH 
DNA is somehow essential for Hdac9 enhancer activity. This hypothesis would suggest 
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the lack of Gata3 in Spretus mice inhibits enhancer functionality. More work must be 
done in this area to fully understand the role of Gata3 in this mechanism of NMSC risk.  
ChIP results also indicate the Oct1 TF selectively binds Spretus murine DNA at the 
Insert 1 Regions 1 and 2 predicted binding sites in vitro.  The potential mechanism for 
Oct1’s role in differential NMSC risk is much more concrete, with evidence supported by 
previously published studies.   
One such study has found that several Oct1 binding sites exist in the promoter region of 
Twist1 (Lee et al. 2013). This study found Oct1 to be part of a repressive binding 
complex with PER2 and other factors including EZH2 and HDAC2. The Oct1-mediated 
complex binds the Twist1 promoter, decreasing expression of Twist1. This mechanism 
would suggest that the selective binding of Oct1 in Spretus mice prevents upregulation 
of Twist1, resulting in reduced expression of Twist1 in comparison to wild-type NIH/Ola 
mice. This trend is exactly what was observed in this project’s qPCR data (Figure 4).  
This repression of Twist1 in cancer resistant Spretus mice would have significant 
implications for NMSC risk, considering Twist1 overexpression is associated with cancer 
phenotypes such as increased cell proliferation, inhibition of apoptosis and increased 
EMT (Geng et al. 2009).  
 
Future Directions and Study Limits 
The majority of experiments in this project focus on enhancer activity demonstrated 
exclusively in Insert 1 of Hdac9 intron 8. A major reason for this narrowed focus has 
been the difficulty of the cloning process, for which only 3 of 9 inserts have successfully 
been cloned. In the future, if more inserts could be successfully cloned, qPCR and ChIP 
studies could be done on additional inserts, limited only by the cost of future Taqman 
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probes and ChIP antibodies. Additionally, it could be beneficial to design primers for later 
portions of Hdac9 exon 8 to see if enhancer activity extends into the nearby exon.  
Only two transcription factors were analyzed in these ChIP studies. In future 
experiments, it could be enlightening to investigate other TFs predicted to differentially 
bind in silico such as AP-1 and Lyf-1 (Table 3).  
Two cell lines were used in this study, A5 and C5N cells, however in some experiments, 
errors in experimental procedure prevented experiment completion in one of the two cell 
lines. Future experiments could repeat these studies in the other cell line to confirm 
results.  
Finally, this study only investigates the activity of this enhancer on genes nearby to 
Hdac9. Enhancers have the capability of affecting gene expression of genes quite far 
from the enhancer site, so other genes could be investigated. C4 studies could be 
conducted to evaluate this potentiality. If more genes are identified as possible targets, 
further qPCR studies could be performed.  
A fundamental limitation of this study is that it does not investigate any other genes or 
regulatory regions in Skts5 that may also play a role in skin cancer susceptibility.  
 
                                                       CONCLUSION 
In summary, I found that variants in Hdac9 intron 8 play a role in an intronic enhancer 
found to upregulate the expression of Twist1. This differential expression of Twist1 
between NIH/Ola and Spretus murine DNA can potentially be explained by the 
differential binding of certain transcription factors including but not limited to Oct1 and 
Gata3. These newly discovered interactions may help explain the role of Hdac9 and 
Skts5 in NMSC risk. 
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